Shades of grey: arguments for and against parallel trade in pharmaceuticals
Competition Law

Shades of grey: arguments for and against parallel trade in pharmaceuticals

Last month the European Court of Justice announced its judgment on Syfait v GlaxoSmithKline, the latest case concerning parallel trading (aka grey imports). One of the most pressing competition issues facing the pharmaceutical industry, this topic was discussed during the second Oxera Economics Council meeting that took place in Brussels on September 15th.

Read More

Open menu Close Search Play video RSS Feed Share on Facebook Share on Twitter Follow us on Instagram Follow us on Youtube Connect with us on Linkedin Email us Copy link